Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials
Authors' conclusion
GLP-1 RAs, SGLT-2is and thiazolidinediones reduced three-point MACE compared with other GLTs. Each drug class had unique advantages and disadvantages.
Study context
- Population
- Multicentre RCTs (>100 participants) of antidiabetic agents vs placebo or another agent reporting MACE or primarily HF; PubMed, Embase, Cochrane43 trials
- Comparison
- 9 types of glucose-lowering therapies vs placebo or each other
- Outcome
- Three-point MACE
Methodological detailsrandom-effects network meta-analysis, multicentre RCTs with >100 participants
- Random-effects network meta-analysis
- Multicentre RCTs with >100 participants
Pooled result
As reported in the abstract
- Risk reduced with GLP-1 RAs, SGLT-2is and thiazolidinediones vs placebo, DPP-4 inhibitors or insulin
Further pooled results
Cardiovascular and renal outcomes
- SGLT-2is reduced renal outcomes, superior to other glucose-lowering therapies (GLTs)
- ≈40%
- GLP-1 RAs favourable for cardiovascular and renal outcomes
HF hospitalization and mortality with thiazolidinediones
- Thiazolidinediones increased risk of hospitalization for HF and had no mortality benefit
Safety
AEs leading to drug discontinuation
- Higher with GLP-1 RAs and thiazolidinediones than placebo
Original publication
Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials. Diabetes Obes Metab. Published 30 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →